Intranasal Drug Delivery Devices Market
Number of pages: 100 | Report Format: PDF | Published date: 14 February, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market size value in 2021 |
US$ 45.75 billion |
|
Revenue forecast in 2030 |
US$ 95.34 billion |
|
Growth Rate |
CAGR of 8.5% from 2022 to 2030 |
|
Base year for estimation |
2021 |
|
Forecast period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments covered |
System, Application, End User, and Region |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
The global intranasal drug delivery devices market was valued at US$ 45.75 billion in 2021 and is expected to witness a CAGR of 8.5% during the forecast period.
Market Fundamental: Definition
Intranasal drug delivery devices are used to administer drugs through the nasal cavity. This method of drug delivery has several advantages over other routes of administration such as oral or intravenous injection. The nasal cavity is lined with a large surface area of blood vessels, which allows for the rapid absorption of drugs into the bloodstream. Additionally, the nasal cavity is directly connected to the central nervous system, making it a useful route of administration for intranasal drugs that need to act quickly. The intranasal drug delivery system also bypasses first-pass metabolism in the liver, which can increase the bioavailability of certain drugs. Some examples of drugs that have been used successfully in intranasal delivery include insulin for people with diabetes, pain relief with fentanyl and sufentanil, anxiety and seizure disorders with midazolam, and opioid overdose with naloxone. Some of the benefits of intranasal drug delivery devices include the non-invasive nature of the administration, convenience, increased patient compliance, targeted delivery to specific regions of the nasal cavity, and reduced side effects. However, it is important to note that not all drugs can be administered intranasally and formulations suitable for intranasal delivery may be different from the standard formulation.
[5756757]
Market Dynamics
The intranasal drug delivery devices market growth is driven by several factors such as an increasingly aging population, a rising prevalence of chronic diseases, and a growing demand for non-invasive treatments. The use of intranasal drug delivery can help to improve patient compliance and satisfaction, which is also expected to drive the market growth. Additionally, advances in the technology are expected to lead in the development of new intranasal drug delivery products and systems, which will also contribute to market growth. One of the key drivers for the intranasal drug delivery devices market is the growing use of intranasal products for pain management and also for the treatment of neurological and psychiatric disorders. This is because of the rapid onset of action provided by intranasal drugs, their ability to target the brain directly and avoid first-pass metabolism, leading to increased bioavailability and reduced side effects. This makes the intranasal route an attractive option for such type of therapies. Another important driver for the market is the growing use of intranasal drug delivery devices in the treatment of allergies and respiratory conditions. The non-invasive nature of these devices, combined with its ability to deliver drugs directly to the site of action, makes it an attractive option for the treatment of these types of conditions. The market is also expected to face certain challenges such as the need for specialized equipment and proper training to administer intranasal drugs, and the cost of such equipment and training can be a barrier to the wider adoption of intranasal drug delivery. Additionally, the development and commercialization of intranasal products can be a challenge due to the regulatory requirements and the need for specific formulations.
Market Ecosystem
The global intranasal drug delivery devices market has been analysed from four perspectives by System, Application, End User, and Region
Intranasal Drug Delivery Devices Market by System
[7567564]
The intranasal drug delivery devices market is segmented by the system into metered-dose, multi-dose, and unit-dose systems. Metered-dose inhalers, also known as MDIs, are devices that deliver a specific amount of medication in the form of a spray or mist. They are commonly used to deliver medications for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Multi-dose systems are drug delivery devices that allow for multiple doses of medication to be delivered from a single device, without the need for re-priming or re-filling the device. In 2021, the market for multi-dose systems held large revenue share. These systems often use pressurized canisters or cartridges to deliver the medication and are commonly used for nasal sprays, metered-dose inhalers (MDIs), and dry powder inhalers (DPIs). On the other hand, unit-dose systems are drug delivery devices that are intended for single use and are discarded after the medication has been used. These systems are often pre-filled with a fixed amount of medication and are commonly used for nasal sprays, inhalers, and other types of intranasal drug delivery devices. Unit-dose systems are cost-effective and convenient, but they create waste as they are single-use only, while multi-dose systems are reusable, which makes it a more economical.
Intranasal Drug Delivery Devices Market by Application
The intranasal drug delivery devices market is segmented into chronic obstructive pulmonary disease (COPD), rhinitis, cystic fibrosis, nasal congestion, asthma, and others. Allergic Rhinitis is the most common condition that causes inflammation of the nasal passages and leads to symptoms like sneezing, runny nose, and nasal congestion. Intranasal drug delivery devices are commonly used for the treatment of allergic rhinitis as it allows for the medication to be delivered directly to the affected area. Migraine is a type of headache characterized by severe pain, often accompanied by nausea, vomiting, and sensitivity to light and sound. Intranasal drug delivery is an attractive option for the treatment of migraine because it allows for rapid pain relief and reduces the likelihood of side effects associated with oral medication. Devices for intranasal medication administration are being used more frequently to treat asthma as well. Asthma affects 1 in 13 people, according to the Centers for Disease Control and Prevention (CDC). Asthma's substantial revenue share is mostly caused by its high incidence as well as ongoing research and development in intranasal drug delivery systems for better absorption. The rhinitis segment will grow significantly at a CAGR throughout the anticipated period. CNS disorders, such as depression and schizophrenia, are conditions that affect the central nervous system and can cause a wide range of symptoms.
Intranasal Drug Delivery Devices Market by End User
The intranasal drug delivery devices market is segmented by end user into hospitals, clinics, homecare, and others. Hospitals are one of the major end users of intranasal drug delivery systems, as these devices are commonly used in the treatment of various conditions such as asthma, COPD, and nasal congestion. They are also used in the treatment of chronic pain and migraines. Clinics are another major end-user of intranasal drug delivery systems, as they provide diagnostic and therapeutic services for various conditions, and intranasal drug delivery systems are used in the treatment of various conditions such as allergies and migraines. Homecare is becoming increasingly popular to treat various conditions, as intranasal drug delivery systems allow patients to self-administer medication in the comfort of their own homes, which is convenient and can help improve adherence to treatment regimens. Other end users may include ambulatory surgical centers, long-term care facilities, nursing homes, and retail pharmacies.
Intranasal Drug Delivery Devices Market by Region
Based on the regional segmentation the global intranasal drug delivery devices market is segmented into North America, Europe, Asia Pacific, and rest of the world. North America held the largest market share in 2021. The prevalence of asthma and chronic obstructive lung disease is rising, and early intervention strategies are frequently employed. The third most common cause of death in the United States is a chronic obstructive pulmonary disease. As a result, the prevalence of COPD is driving the use of nasal medication delivery systems. Due to increased R&D spending, an increase in the frequency of chronic diseases, and growing public awareness, the Asia Pacific market is anticipated to grow at fastest CAGR during the forecast period. Growth potential is created by the expanding patient population and the existence of significant healthcare providers in quickly developing nations like China and India. Government spending is also driving up healthcare revenue in the Asia Pacific region.
Competitive Landscape
Some of the most prominent competing companies of global intranasal drug delivery devices market are,
Strategic Development
Intranasal drug delivery is a method of administering medication through the nose, into the nasal passages, that offers advantages such as rapid onset of action, high bioavailability, and the ability to bypass the gastrointestinal tract and liver.
Key trends in intranasal drug delivery devices include increasing use for the treatment of neurological disorders, the growing geriatric population, rising demand for non-invasive drug delivery methods, and advances in technology.
Key companies operating the global intranasal drug delivery devices market are OptiNose, Inc., Becton, Dickinson and Company, LLC, B.F. Ascher & Company, Inc., PendoPharm, Inc., Douglas Pharmaceuticals Ltd., ENT Technologies Pty. Ltd., NAVEH Pharma Ltd.
Market restraints for intranasal drug delivery include a lack of awareness, high costs associated with the development of intranasal products, and regulatory challenges.
The global intranasal drug delivery market is expected to witness a CAGR of 8.5% during the forecast period.
*Insights on financial performance are subject to the availability of information in the public domain
Using the fundamental research and knowledge services capabilities of GRG Health, Growth Plus Reports may now be tailored based on client needs.
GRG Health's unique GrowthMIX strategy and comprehensive research methodology enable us to provide unique and valuable insights to our clients while uncovering trends that would not be discovered using traditional techniques.
Snehal Deshmukh
Principle Consultant
Speak to analyst